A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

October 7, 2020

Study Completion Date

October 7, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.

Trial Locations (23)

17033

Penn State Hershey Medical Center, Hershey

27612

Wake Research Associates Llc, Raleigh

31904

Iact Health, Columbus

33142

Acevedo Clinical Research, Miami

33145

Floridian Research Institute Llc, Miami

33174

Rm Medical Research Inc, Miami

33609

Olympian Clinical Research, Tampa

33770

Olympian Clinical Research, Largo

35244

Cahaba Dermatology, Hoover

45414

Ohio Pediatric Research Association, Dayton

46168

The Indiana Clincal Trials Center, Plainfield

48103

David Fivenson, Md, Pllc, Ann Arbor

60611

Northwestern University, Chicago

72212

Applied Research Center of Arkansas, Little Rock

78213

Progressive Clinical Research, San Antonio

78218

Texas Dermatology and Laser Specialists, San Antonio

80206

National Jewish Health, Denver

83713

Advanced Clinical Research, Boise

85295

Desert Sky Dermatology, Gilbert

90027

Children'S Hospital Los Angeles Specialt, Los Angeles

92123

Rady Children'S Hospital - San Diego, San Diego

92801

Orange County Research Center, Anaheim

97030

Cyn3Rgy Research - Clinedge - Ppds, Gresham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT03257644 - A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | Biotech Hunter | Biotech Hunter